Latest news with #NEOG
Business Wire
3 days ago
- Business
- Business Wire
Securities Fraud Investigation Into Neogen Corporation (NEOG) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Neogen Corporation ('Neogen' or the 'Company') (NASDAQ: NEOG) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON NEOGEN CORPORATION (NEOG), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On June 4, 2025, Neogen disclosed that, while its fourth quarter fiscal 2025 financial results would be 'materially approximate [to] where [the Company] had put [its] guide,' it 'would expect EBITDA margin to probably be around the high-teens' compared to the previous quarter's 22%. The Company explained that EBITDA margins would likely 'be in the low-20s, if not for the elevated inventory write-offs.' On this news, Neogen's stock price fell $1.04, or 17.3%, to close at $4.96 per share on June 4, 2025, thereby injuring investors. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us. Charles Linehan, Esq., Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150 (Toll-Free: 888-773-9224) Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. Whistleblower Notice Persons with non-public information regarding Neogen should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@ About Glancy Prongay & Murray LLP Glancy Prongay & Murray LLP ('GPM') is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPM has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements. With four offices across the country, GPM's nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPM's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
5 days ago
- Business
- Business Wire
Neogen Launches Second Edition Environmental Monitoring Handbook to Elevate Food Safety Practices
BUSINESS WIRE)--In recognition of World Food Safety Day, Neogen® Corporation (NASDAQ: NEOG) today announced the release of the Second Edition Neogen Environmental Monitoring Handbook, a comprehensive resource designed to help food and beverage manufacturers strengthen food safety programs and reduce contamination risks. The updated guide introduces critical new insights on validating risk-based controls, conducting root cause analysis, and leveraging data for continuous improvement, providing food safety professionals with science-backed strategies to enhance their environmental monitoring programs. 'Environmental monitoring is a critical strategy for promoting food safety and quality,' said Dr. Martin Wiedmann, Gellert Family Professor of Food Safety at Cornell University. Share A Trusted Resource, Now More Essential Than Ever Environmental monitoring is a critical component of food safety programs, involving sampling and testing the environment and equipment within a food manufacturing facility to help prevent cross-contamination of finished products. The Second Edition Neogen Environmental Monitoring Handbook builds on the success of its predecessor with three new chapters covering: Using environmental monitoring to validate non-process controls and prerequisite programs Best practices for conducting root cause analysis after contamination events Data management and utilization in environmental monitoring programs 'With rising expectations across the food industry, environmental monitoring remains one of the most powerful tools for reducing contamination risk,' said Cari Lingle, Senior Manager, Global Learning Experience at Neogen. 'This handbook offers practical, expert-driven guidance to help manufacturers strengthen their monitoring strategies, validate and verify sanitation practices, and elevate food safety with confidence.' 'Environmental monitoring is a critical strategy for promoting food safety and quality,' said Dr. Martin Wiedmann, Gellert Family Professor of Food Safety at Cornell University. 'It has been a pleasure to work with Neogen to expand the scope of this handbook with new insights and real-world applications. We aim to equip food safety professionals with tools to take a holistic, integrated approach—one that connects the dots across food safety systems to drive proactive risk mitigation, regulatory compliance, and continuous improvement. Ultimately, these efforts help safeguard product integrity and strengthen business operations and brand reputation.' A Continued Commitment to Food Safety Excellence The release of the Second Edition Neogen Environmental Monitoring Handbook underscores Neogen's dedication to advancing global food safety. As the industry marks World Food Safety Day, this resource provides timely, expert-driven guidance to help manufacturers safeguard their products and consumers. The Second Edition Neogen Environmental Monitoring Handbook is available now. Download a copy at About Neogen Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.
Yahoo
20-05-2025
- Business
- Yahoo
Neogen Stock Gains Following Strategic Alliance With Syngenta
Neogen Corporation NEOG has recently entered into a strategic licensing and supply agreement with Syngenta. Under the agreement, Neogen will have exclusive rights to market and sell Talon-G and Talon Weatherblok XT rodenticides in the United States and Canada. The agreement is likely to expand Neogen's rodenticide portfolio with well-established and highly effective products. Following the announcement, shares of NEOG moved 4.7% north to $6.70 in yesterday's after-market trading session. Neogen follows several growth strategies to be the leading company in the development and marketing of solutions for food and animal safety. One of the strategies is acquiring businesses and forming strategic alliances. In line with this, Neogen formed a genomics relationship with Performance Food Group last fiscal year. With this, it became the official genomics provider for the food group's PathProven service. Furthermore, in the fiscal third quarter of 2025, the company completed the merger of the 3M Food Safety Division. Henceforth, we expect market sentiment to remain positive surrounding the announcement of the latest development. NEOG currently has a market capitalization of $1.43 billion. It has an earnings yield of 5.75% compared with the industry's 0.04%. The Zacks Consensus Estimate for fiscal 2026 earnings is pegged at 44 cents per share, which suggests 17.1% growth from the fiscal 2025 reported number. Under the agreement, Neogen will leverage its commercial and technical expertise to lead the promotion and distribution of Talon-G and Talon Weatherblok XT. Meanwhile, Syngenta will focus more on its long-term vision of bringing new, innovative pest control technologies to market. For investors' note, Talon-G and Talon Weatherblok XT, containing the active ingredient brodifacoum, are second-generation anticoagulant rodenticides that can control rodents with a single feeding. This agreement reinforces Neogen's commitment to providing comprehensive pest management solutions and strengthens its ability to serve customers across North America. Per a TechSci Research report, the global rodenticides market was valued at $6.34 billion in 2024 and is expected to reach $8.64 billion by 2030 at a compound annual growth rate of 5.3% during the period. The rodenticides market plays a crucial role in the pest control industry, providing essential solutions to mitigate the impact of rodent infestations on various sectors, including agriculture, urban areas and industrial facilities. One of the key drivers of the rodenticides market is the persistent challenge posed by rodent-borne diseases and damage to crops. Image Source: Zacks Investment Research Earlier this year, Neogen launched its new Neogen Molecular Detection Assay 2 – Quantitative Salmonella (MDA2QSAL96). This assay helps overcome certain limitations of existing solutions with improved sensitivity and accuracy and an easy-to-use workflow. Molecular Detection Assay 2 - Quantitative Salmonella is the latest addition to the company's Molecular Detection System pathogen testing platform. In late 2024, Neogen introduced the Petrifilm Bacillus cereus Count Plate. This solution offers food safety professionals a simple, reliable, and efficient testing method for Bacillus cereus. Petrifilm Bacillus cereus Count Plate is the latest addition to the company's Petrifilm product line. In the past year, NEOG's shares have lost 53.1% against the industry's 10.7% growth. Neogen currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the broader medical space are AngioDynamics ANGO, STERIS STE and DexCom DXCM. AngioDynamics, carrying a Zacks Rank #1 (Strong Buy) at present, has an estimated earnings growth rate of 23.7% for 2025. You can see the complete list of today's Zacks #1 Rank stocks here. ANGO's earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 70.85%. Veracyte's shares have risen 49.2% in the past year compared with the industry's 5.5% growth. STERIS, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 10.8% for 2025. STE's earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 0.61%. Its shares have risen 34.1% compared with the industry's 7.7% growth in the past year. DexCom, carrying a Zacks Rank #2 at present, has an estimated earnings growth rate of 23.2% for 2025. Its earnings surpassed estimates in two of the trailing four quarters and missed in the other two, delivering an average surprise of 0.47%. DXCM's shares have risen 26.4% against the industry's 15.7% decline in the past year. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report Neogen Corporation (NEOG) : Free Stock Analysis Report STERIS plc (STE) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
05-05-2025
- Business
- Yahoo
3 Value Stocks with Questionable Fundamentals
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models. Separating the winners from the value traps is a tough challenge, and that's where StockStory comes in. Our job is to find you high-quality companies that will stand the test of time. That said, here are three value stocks with little support and some other investments you should consider instead. Forward P/E Ratio: 11.5x As the world's largest manufacturer of autonomous mobile robots, Tennant (NYSE:TNC) designs, manufactures, and sells cleaning products to various sectors. Why Is TNC Not Exciting? Annual revenue growth of 2.3% over the last five years was below our standards for the industrials sector Sales are projected to tank by 1% over the next 12 months as demand evaporates Free cash flow margin dropped by 7.1 percentage points over the last five years, implying the company became more capital intensive as competition picked up Tennant's stock price of $71.48 implies a valuation ratio of 11.5x forward P/E. Check out our free in-depth research report to learn more about why TNC doesn't pass our bar. Forward P/E Ratio: 11.3x Founded in 1981 and operating at the intersection of food safety and animal health, Neogen (NASDAQ:NEOG) develops and manufactures diagnostic tests and related products to detect dangerous substances in food and pharmaceuticals for animal health. Why Should You Dump NEOG? Earnings per share fell by 7.5% annually over the last five years while its revenue grew, showing its incremental sales were much less profitable Waning returns on capital from an already weak starting point displays the inefficacy of management's past and current investment decisions Limited cash reserves may force the company to seek unfavorable financing terms that could dilute shareholders At $5.75 per share, Neogen trades at 11.3x forward P/E. Dive into our free research report to see why there are better opportunities than NEOG. Forward P/E Ratio: 2.5x Spun off from Merck in 2021 to create a company dedicated to addressing unmet needs in women's health, Organon (NYSE:OGN) is a global healthcare company focused on improving women's health through prescription therapies, medical devices, biosimilars, and established medicines. Why Should You Sell OGN? Annual sales declines of 3.8% for the past five years show its products and services struggled to connect with the market during this cycle Earnings per share have dipped by 18% annually over the past four years, which is concerning because stock prices follow EPS over the long term Free cash flow margin dropped by 28.9 percentage points over the last five years, implying the company became more capital intensive as competition picked up Organon is trading at $9.57 per share, or 2.5x forward P/E. To fully understand why you should be careful with OGN, check out our full research report (it's free). The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years. Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like United Rentals (+322% five-year return). Find your next big winner with StockStory today for free. Sign in to access your portfolio
Yahoo
23-04-2025
- Business
- Yahoo
Is Neogen Corporation (NEOG) The Top Falling Stock with Unusual Volume?
We recently published a list of . In this article, we are going to take a look at where Neogen Corporation (NASDAQ:NEOG) stands against other top falling stocks with unusual volume. Uncertainty around tariffs and macroeconomic conditions has dented investor confidence, resulting in stock prices falling. While some stocks have come under pressure due to the above two reasons, others have simply followed the market direction or have dipped for company-specific reasons. Regardless of the reasons for stocks going down, falling stocks provide an opportunity for fresh investors to get in at good prices. Once the risks subside, these stocks usually recover quickly as well. We decided to uncover these stocks and see if it makes sense to put money in them to take advantage of the ongoing market turmoil. To come up with our list of top 20 stocks falling with unusual volume, we looked at stocks over $300 million in market cap, their one-week performance, and used relative volume to detect the unusual volume activity. Relative volume compares the daily volume to the three-month average trading volume of the stock, making it easy to detect spikes in volume. These spikes usually signal something important is happening, which, when combined with falling prices, becomes a red flag that investors can't ignore. A research laboratory showing advanced diagnostic equipment used to protect public health. Neogen Corporation (NASDAQ:NEOG) is the manufacturer, developer, and marketer of different products and services focused on animal and food safety. The company operates in the Animal Safety and Food Safety segments. The stock is down 22.02% in a week on a relative volume of 2.69. Neogen missed both revenue and Non-GAAP EPS estimates in Q3. Revenue declined by 3.4% YoY while non-GAAP EPS missed by $0.02. The company lowered its Q4 2025 guidance due to the lower-than-expected third quarter results. As per the updated revenue guidance, the firm now projects Q4 revenue to be approximately $895 million. Expected capital expenditures are $100 million with adjusted EBITDA of about $195 million. At the start of this month, Neogen Corporation (NASDAQ:NEOG) announced the successful refinancing of its debt. As per the new agreement, a $250 million revolving credit facility and a $450 million term loan have a maturity date of August 2027. With the help of this new deal, the maturity date has been extended by over two and a half years. CFO and COO of Neogen Corporation (NASDAQ:NEOG), David Naemura, said: 'The new term loan and revolving credit facility provide us with additional balance sheet flexibility, and we appreciate the support of our entire bank group throughout the process.' Overall, NEOG ranks 3rd on our list of top falling stocks with unusual volume. While we acknowledge the potential of NEOG as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than NEOG but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: and . Disclosure: None. This article is originally published at . Sign in to access your portfolio
